Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaTeVac in Soft Tissue Sarcoma
NCT01883518Phase 2Unknown
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Start
- Jun 2013
- Primary completion
- Sep 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of CaTeVac in soft tissue sarcoma (STS), sponsored by N.N. Petrov National Medical Research Center of Oncology. Status: unknown.
02
Drugs
CaTeVac
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01883518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01883518.